SIGA Technologies' stock has declined 37% since a previous 'speculative buy' recommendation due to a muted response to the mpox outbreak. The initial recommendation was based on the WHO's mpox emergency declaration and potential increased demand for SIGA's lead asset, tecovirimat. However, the outbreak has waned, and global authorities' response has been less aggressive, leading to lower-than-expected demand for tecovirimat.